TGA approves seven new drugs

Posted 31 March 2025 AM

Last week, the TGA approved a massive seven new products, including AstraZeneca’s long-awaited asthma biologic Tezspire, along with the first-ever generic of Chiesi's Fostair. 

Tezspire, also known as tezepelumab is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma who are inadequately controlled despite optimal therapy including medium or high dose inhaled corticosteroids plus another non-steroidal medicinal product for maintenance treatment.

To see the whole article, please login